Malouff TD, Stross WC, Seneviratne DS et al (2020) Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: a national cancer database analysis. Prostate Cancer Prostatic Dis 23:349–355

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network Prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 8 May 2024

Rowe LS, Mandia JJ, Salerno KE et al (2022) Bowel and bladder reproducibility in image guided radiation therapy for prostate cancer: results of a patterns of practice survey. Adv Radiat Oncol 7:100902

Article  PubMed  PubMed Central  CAS  Google Scholar 

Levin-Epstein RG, Jiang NY, Wang X et al (2021) Dose-response with stereotactic body radiotherapy for prostate cancer: a multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiother Oncol 154:207–213

Article  PubMed  CAS  Google Scholar 

Jackson WC, Silva J, Hartman HE et al (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104:778–789

Article  PubMed  PubMed Central  Google Scholar 

Mesci A, Isfahanian N, Dayes I, Lukka H, Tsakiridis T (2022) The journey of radiotherapy dose escalation in high risk prostate cancer; conventional dose escalation to stereotactic body radiotherapy (SBRT) boost treatments. Clin Genitourin Cancer 20:e25–e38

Article  PubMed  Google Scholar 

Gorovets D, Wibmer AG, Moore A et al (2023) Local failure after prostate SBRT predominantly occurs in the PI-RADS 4 or 5 dominant Intraprostatic lesion. Eur Urol Oncol 6:275–281

Article  PubMed  Google Scholar 

Hall WA, Tree AC, Dearnaley D et al (2021) Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol 22:11–13

Article  PubMed  PubMed Central  Google Scholar 

Giuliani J, Fiorica F (2021) Cost-effectivess of SpaceOAR system during prostate cancer radiation therapy: really helpful or excess of expectations? Brachytherapy 20:1341–1342

Article  PubMed  Google Scholar 

Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340–351

Article  PubMed  Google Scholar 

Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo IK, Bangma C (2013) Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol 8:84

Article  PubMed  PubMed Central  Google Scholar 

Herrera FG, Valerio M, Berthold D et al (2019) 50-Gy stereotactic body radiation therapy to the dominant intraprostatic nodule: results from a phase 1a/b trial. Int J Radiat Oncol Biol Phys 103:320–334

Article  PubMed  Google Scholar 

Monninkhof EM, van Loon JWL, van Vulpen M et al (2018) Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol 127:74–80

Article  PubMed  Google Scholar 

Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39:787–796

Article  PubMed  CAS  Google Scholar 

Tree AC, Satchwell L, Alexander E et al (2023) Standard and hypofractionated dose escalation to Intraprostatic tumor nodules in localized prostate cancer: 5‑year efficacy and toxicity in the DELINEATE trial. Int J Radiat Oncol Biol Phys 115:305–316

Article  PubMed  Google Scholar 

Zamboglou C, Spohn SKB, Ruf J et al (2022) PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2‑armed phase 2 trial (ARO2020-01). Int J Radiat Oncol Biol Phys 113:1025–1035

Article  PubMed  Google Scholar 

Draulans C, van der Heide UA, Haustermans K et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 147:92–98

Article  PubMed  Google Scholar 

Alayed Y, Davidson M, Liu S et al (2020) Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: a toxicity and quality-of-life comparison of two prospective trials. Int J Radiat Oncol Biol Phys 107:136–142

Article  PubMed  Google Scholar 

Hannan R, Salamekh S, Desai NB et al (2022) SAbR for high-risk prostate cancer—a prospective multilevel MRI-based dose escalation trial. Int J Radiat Oncol Biol Phys 113:290–301

Article  PubMed  Google Scholar 

Correa RJM, Davidson MTM, Liu SK et al (2022) Five-fraction stereotactic ablative radiotherapy to the pelvis and prostate with focal intra-prostatic boost: outcomes of the 5STAR trial. Int J Radiat Oncol Biol Phys 114:S132

Article  Google Scholar 

Morris BA, Holmes EE, Anger NJ et al (2023) Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging-identified prostate cancer lesions: results of a phase 2 trial. Int J Radiat Oncol Biol Phys 117:613–623

Article  PubMed  Google Scholar 

Widmark A, Gunnlaugsson A, Beckman L et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385–395

Article  PubMed  Google Scholar 

Tree AC, Ostler P, van der Voet H et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2‑year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308–1320

Article  PubMed  Google Scholar 

Gao Z, Wilkins D, Eapen L, Morash C, Wassef Y, Gerig L (2007) A study of prostate delineation referenced against a gold standard created from the visible human data. Radiother Oncol 85:239–246

Article  PubMed  Google Scholar 

Musunuru HB, Davidson M, Cheung P et al (2016) Predictive parameters of symptomatic hematochezia following 5‑fraction gantry-based SABR in prostate cancer. Int J Radiat Oncol Biol Phys 94:1043–1051

Article  PubMed  Google Scholar 

Correa RJM, Loblaw A (2022) Stereotactic body radiotherapy: hitting harder, faster, and smarter in high-risk prostate cancer. Front Oncol 12:889132

Article  PubMed  PubMed Central  Google Scholar 

Wang K, Mavroidis P, Royce TJ et al (2021) Prostate stereotactic body radiation therapy: an overview of toxicity and dose response. Int J Radiat Oncol Biol Phys 110:237–248

Article  PubMed  Google Scholar 

Lapierre A, Hennequin C, Beneux A et al (2022) Highly hypofractionated schedules for localized prostate cancer: recommendations of the GETUG radiation oncology group. Crit Rev Oncol Hematol 173:103661

Article  PubMed  Google Scholar 

Alayed Y, Quon H, Ong A et al (2020) Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol 149:8–13

Article  PubMed  CAS  Google Scholar 

Thames HD, Kuban D, Levy LB et al (2010) The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 96:6–12

Article  PubMed  Google Scholar 

Zilli T, Jorcano S, Bral S et al (2023) Every-other-day versus once-a-week urethra-sparing prostate stereotactic body radiation therapy: 5‑year results of a randomized phase 2 trial. Int J Radiat Oncol Biol Phys 117:791–798

Article  PubMed  Google Scholar 

van Dams R, Jiang NY, Fuller DB et al (2021) Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients. Int J Radiat Oncol Biol Phys 110:731–737

Article  PubMed  PubMed Central  Google Scholar 

Alayed Y, Cheung P, Vesprini D et al (2019) SABR in high-risk prostate cancer: outcomes from 2 prospective clinical trials with and without elective nodal irradiation. Int J Radiat Oncol Biol Phys 104:36–41

Article  PubMed  Google Scholar 

Fuller DB, Crabtree T, Kane BL et al (2022) High dose “HDR-like” prostate SBRT: PSA 10-year results from a mature, multi-institutional clinical trial. Front Oncol 12:935310